- Service Name
VIASKIN® patch
- Industry
Biopharmaceutical, healthcare, immunotherapy, allergy treatment
- Main Value Proposition
The primary value offered is a safe and effective treatment for food allergies, aiming to transform the lives of patients with unmet medical needs.
- Description
The VIASKIN® patch is an innovative epicutaneous immunotherapy designed to treat food allergies, particularly peanut and cow's milk allergies. It aims to re-educate the immune system by delivering small amounts of allergens through the skin.
- Key Features
Epicutaneous immunotherapy (EPIT) technology; Targeted treatment for peanut and cow's milk allergies; Ongoing clinical trials with promising results; Potential to re-educate the immune system
- Use Cases
The service is most valuable in scenarios involving children and adolescents with diagnosed food allergies, particularly those at risk of severe allergic reactions.
- Competitive advantages
Innovative delivery method that minimizes risk of severe allergic reactions; Focus on pediatric patients, addressing a critical demographic; Strong clinical research backing with ongoing trials and studies
- Strengths
Key strengths include a robust development program, a focus on safety and efficacy, and a commitment to addressing a significant global health issue related to food allergies.
- Positioning
DBV Technologies positions itself as a leader in innovative biopharmaceutical solutions for food allergies, focusing on safety and efficacy in treatment.
- Audience
The target users include parents of children with food allergies, healthcare providers specializing in immunology, and researchers in the field of allergy treatment.
- CTA
Learn more
- Tags
food allergies
immunotherapy
pediatric treatment
clinical trials
- Tagline
Dedicated to Improving the Lives of Patients with Food Allergies and Other Immunological Diseases
- Tone of Voice
Innovative, compassionate, professional
- Differentiation
The VIASKIN® patch utilizes a novel approach of delivering allergens through the skin, which is different from traditional oral or injectable therapies, making it a unique solution in the market.
- Brand Positioning
The brand identity emphasizes a commitment to improving patient lives through cutting-edge science and compassionate care.
- Founded
2002-01-01
- Founders
Bertrand Dupont
Christophe Dupont
Pierre Benhamou